The world's first vaccine against dengue, developed by French drugmaker Sanofi, has shown the ability to protect against disease caused by three of four dengue virus strains in a keenly awaited clinical trial in Thailand.
Sanofi said on Wednesday the proof of efficacy was "a key milestone" in the 70-year quest to develop a viable dengue shot, adding the results also confirmed the safety profile of the vaccine candidate.
The mosquito-borne disease - also known as "breakbone fever" - is a threat to nearly 3 billion people and is caused by four different types of virus, none of which confers immunity from the others.
Sanofi's vaccine generated an antibody response for all four dengue virus types, but evidence of protection was only demonstrated against three of the four circulating in Thailand. Sanofi said researchers were carrying out analyses to understand the lack of protection for the fourth serotype.
The company's vaccine unit, Sanofi Pasteur, has already invested 350 million euros ($423 million) in a new French factory to make the three-dose vaccine and believes its product could generate 1 billion euros in yearly sales.
But uptake of the vaccine will depend on precisely how well doctors believe it can protect populations at risk in fast-expanding tropical cities from Rio to Manila, as well as travelers.
Sanofi gave no details on the level of protection in a brief statement. The full data are now being reviewed by scientific experts and public health officials, with detailed results to be published later this year.
Sanofi previously said it planned to present the findings at the annual meeting of the American Society of Tropical Medicine and Hygiene in Atlanta in November.
Large-scale late-stage Phase III clinical studies with 31,000 participants are under way with Sanofi's vaccine in 10 countries in Asia and Latin America.
Researchers monitoring these patterns estimate as many as 35,000 walruses came to shore near the coastal village of Point Lay, about 700 miles (1130 km) north of Anchorage at the weekend.
The Centers for Disease Control and Prevention confirms a patient at a hospital in Dallas, Texas, was diagnosed with the Ebola virus.
The Saudi Arabian national was being treated in an isolation ward in a hospital in Vienna and all people she had been in contact with would be informed and checked for symptoms
The death toll has risen to at least 3,091 out of 6,574 probable, suspected and confirmed cases.
In the study of 50 non-small cell lung cancer patients with a rearrangement of the ROS1 gene, Xalkori treatment led to significant tumor shrinkage in 36 of them, or 72 percent, and halted tumor growth in an additional 9 patients.
The second contingent of 296 doctors and nurses will head to Liberia and Guinea, the official news agency Prensa Latina said on Friday.
Part of a broad tax reform, Chile's carbon tax will target the power sector, particularly generators operating thermal plants with installed capacity equal or larger than 50 megawatts (MW).
Priest Manuel Garcia Viejo, 69, passed away after having caught virus while working in Sierra Leone.
Malaria, diarrhoea, pneumonia threaten many more lives as fear of Ebola means sick people are avoiding clinics and death toll among health workers has left few staff
Health officials issue alerts as the number of suspected cases of the chikingunya virus approach 1 million.
Rabies remains a threat to half the world's people and about 40 percent of victims are children, the experts said.
U.S. President Barack Obama called on more nations to help fight the world's worst outbreak of the deadly Ebola virus, saying hundreds of thousands of lives were at stake.
India's Supreme Court ruled that 214 coal mining licenses granted between 1993 and 2010 were "illegally and arbitrarily" allocated.
WHO advisers earlier recommended the screening of travellers departing Ebola-affected countries from airports and ports.
Several islands had been abandoned in Kiribati partly because low-lying farmland was becoming less productive as storm surges whipped more salt onto the land